Journal
KIDNEY INTERNATIONAL
Volume 83, Issue 3, Pages 343-345Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/ki.2012.412
Keywords
-
Categories
Ask authors/readers for more resources
Multiple-relapsing minimal-change disease (MCD) often requires exposure to potentially toxic agents in an attempt to achieve a lasting remission of nephrotic syndrome. Munyentwali and co-workers describe an experience using rituximab in adults with multiple-relapsing MCD that supports both efficacy and safety of this agent. However, the optimal dosing regimen and mechanism of action remain unclear. Thus, randomized controlled trials are warranted in both adults and children to better define the role of rituximab in multiple-relapsing MCD. Kidney International (2013) 83, 343-345. doi:10.1038/ki.2012.412
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available